Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researchers Discover New Rx For Allergic Contact Dermatitis

By Louisiana State University Health Sciences Center | March 22, 2018

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, has found a promising new treatment for allergic contact dermatitis that offers an alternative to corticosteroids and their possible side effects. The research is published this month in Dermatology and Therapy, available here.

Working in an experimental model of allergic contact dermatitis, the research team developed a mixture of antioxidants and moisturizers, combined with potent free radical scavengers and inhibitors, which suppressed an inflammatory response to the irritant. The cream relieved itch, reduced swelling and protected peripheral nerves in the affected area.

Allergic contact dermatitis (ACD) is caused by exposure to an allergen in sensitive people. Sensitizing allergens include nickel and gold, perfumes, soaps or organic compounds. Although removal of the allergen reduces symptoms, recovery can take weeks. The authors also note that allergic contact dermatitis represents 5-10% of doctor visits.

One of the current primary treatments for severe allergic contact dermatitis is the use of corticosteroids. Long-term use of corticosteroids can result in skin atrophy, spider veins, loss of skin color or corticosteroid acne. They can disrupt the skin’s barrier and lead to adrenal suppression, altered growth, hypertension, hyperglycemia, insulin resistance and cataracts, and they may increase the risk for certain cancers. 

The experimental cream, on the other hand, successfully treated allergic contact dermatitis in mice, without the side effects of corticosteroids. The new cream works in a different way by preventing or stopping the process that initiates inflammation.

This project is part of a long collaboration that Dr. Bazan developed with Dr. Ricardo Palacios-Pelaez from Spain on inflammation, immunity and neurodegenerative diseases. 

“Now with the new cream, we targeted some of those mechanisms in a relatively less complex condition in the skin, always with translational-enabling goals,” said Bazan.

Other members of the research team included Drs. William Gordon, Surjyadipta Bhattacharjee and Bokkyoo Jun at LSU Health New Orleans Neuroscience Center of Excellence, as well as Drs. Virginia Garciá López, David Rodríguez Gil, Javier Alcover Díaz, Fernando Pineda de la Losa, Ricardo Palacios Peláez, Concha Tiana Ferrer and Gabriela Silvina Bacchini from Madrid, Spain; along with Hélène Varoqui at Ochsner.

“While our results are very promising, additional studies are needed to determine the ideal duration of treatment and the most efficacious concentrations of the active components in the test formulations that will best alleviate ACD,” Bazan concluded. 

The research was supported by a grant from the National Institute of General Medical Sciences, as well as LSU Health New Orleans Neuroscience Center of Excellence.

This work is part of Bazan’s innovative research searching for novel fundamental principles of tissue/organ injury involving inflammation, immunology, genetics and epigenetics. Most of his efforts are focused on responses to damage to the brain and retina and include Parkinson’s, Alzheimer’s, pain, Macular degeneration and traumatic brain injury, but as these findings demonstrate, fundamental discoveries have broad application.

(Source: EurekAlert!)


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE